Language Select
Varian Logo

Press Releases

June 29, 2017
Varian Medical Systems (NYSE: VAR) has received FDA 510(k) clearance for its Halcyon™ system, its new device for cancer treatment. Halcyon simplifies and enhances virtually every aspect of... Read more
June 26, 2017
Varian Medical Systems (NYSE: VAR) announced today that it will report results for the third quarter of fiscal year 2017 following the close of regular trading on Wednesday, July 26, 2017. The... Read more
June 22, 2017
A significant milestone for the UK's first National Health Service high energy proton therapy center occurred today when Varian Medical Systems (NYSE: VAR) delivered the cyclotron to the new... Read more
June 21, 2017
In the first project of its kind outside the United States, Varian Medical Systems (NYSE: VAR) is working with Sify Technologies to provide software-as-a-service (SaaS) to radiotherapy centers... Read more
June 20, 2017
Varian Medical Systems (NYSE: VAR) announced it has successfully installed a Varian ProBeam cyclotron at the National Centre for Particle Therapy in Aarhus, Denmark. The installation of the... Read more
June 15, 2017
Varian Medical Systems (NYSE: VAR) is spotlighting its new Halcyon™ radiotherapy treatment system at the 2017 meeting of DEGRO, the German radiation oncology society, which takes place in Berlin... Read more
June 05, 2017
Varian Medical Systems (NYSE: VAR) today announced it has signed an agreement with Vijametech and UPMC, to develop plans for future radiation oncology centers in Vietnam. Collaborating with the... Read more
May 25, 2017
Clinical experts in stereotactic radiosurgery will discuss new techniques using Varian Medical Systems' (NYSE:VAR) Edge™ radiosurgery system for the noninvasive, simultaneous treatment of... Read more
May 24, 2017
Varian Medical Systems (NYSE: VAR), today announced it has been selected through its distributor, Business Alignment, to supply and install a Varian ProBeam® Compact single-room proton therapy... Read more
May 10, 2017
Varian Medical Systems (NYSE: VAR) today announced it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the ProBeam® system for proton therapy... Read more

Corporate Communications Contact

Mark Plungy
Director, Public Relations
650.424.5630
[email protected]

Investor Relations Contact

Mike Bruff
SVP, Investor Relations
650.424.5163
[email protected]

Monica Prokocki
Director, Investor Relations
650.424.5184
[email protected]